{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:32:09Z","timestamp":1795059129979,"version":"4.10.2"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:sec id=\"ab-coi250008-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Surgical resection of pancreatic ductal adenocarcinoma (PDAC) modestly improves long-term survival due to the competing risk of metastatic disease. However, postoperative morbidity often interferes with administration of systemic therapy and may be unacceptable to some patients. Ablative radiation therapy (A-RT) has emerged as an effective noninvasive local treatment in many tumor types and may provide an alternative to surgery in select patients with resectable PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250008-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the efficacy of A-RT in technically resectable PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250008-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study of consecutive patients with histologically confirmed, radiographically resectable T1-2N0-1M0 PDAC treated with A-RT at Memorial Sloan Kettering Cancer Center between June 2016 and December 2022 were included from a prospectively maintained database. Patients were not eligible for surgery because of noncancer-related comorbidities. Data were frozen for analysis in December 2023, which took place between March and November 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250008-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>All patients received A-RT exceeding 97.5-Gy biologically effective dose with daily computed tomography or magnetic resonance imaging guidance, motion management, and daily or selective adaptation of the dose distribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250008-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was overall survival (OS). Secondary outcomes included biochemical and radiographic objective response rate, cumulative incidence of local progression, progression-free survival, and distant metastasis\u2013free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250008-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 25 patients with radiographically resectable PDAC who received A-RT, 13 (52%) were male, and the median (IQR) age at time of A-RT was 80 (74-87) years. A total of 20 patients (80%) had a Karnofsky Performance Status score of 80 or lower. A total of\u200915 tumors (60%) were T2, and 4 (16%) were node positive. A total of 17 patients (68%) received induction chemotherapy for a median (range) of 2.9 (1.0-6.1) months. Radiation therapy regimens delivered with conventional linear accelerators included 75 Gy in 25 fractions among 13 patients, 67.5 Gy in 15 fractions among 9 patients, 50 Gy in 5 fractions among 2 patients (magnetic resonance imaging-guided linear accelerator), and 60 Gy in 10 for 1 patient. OS, local progression, and distant metastasis\u2013free survival at 2 years were 43.7% (95% CI, 27.4%-69.5%), 20.8% (95% CI, 7.3%-39.0%), and 20.0% (95% CI, 9.1%-43.8%), respectively. Grade 3 acute and late gastrointestinal tract toxic effects were noted in 3 and 1 patients, respectively, with no grade 4 or higher events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250008-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this cohort study, A-RT in patients with technically resectable PDAC led to effective local tumor control and favorable OS despite advanced age, poor Karnofsky Performance Status score, and conservative use of chemotherapy in the cohort studied. These data support a prospective study of A-RT for the management of resectable PDAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.0460","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:00:34Z","timestamp":1744282834000},"page":"609","source":"Crossref","is-referenced-by-count":17,"title":["Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy"],"prefix":"10.1001","volume":"11","author":[{"given":"Marsha","family":"Reyngold","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"},{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Varghese","sequence":"additional","affiliation":[{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"},{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"White","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Zinovoy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Romesser","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"Oncology Institute at Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Cuaron","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny N.","family":"Khalil","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wungki","family":"Park","sequence":"additional","affiliation":[{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"},{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Yu","sequence":"additional","affiliation":[{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"},{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi250008r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016.","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"10073","key":"coi250008r2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"9293","key":"coi250008r3","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"coi250008r4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"coi250008r5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"issue":"11","key":"coi250008r6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial.","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"coi250008r7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma.","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"issue":"11","key":"coi250008r8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial.","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"issue":"1","key":"coi250008r9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/01.sla.0000217673.04165.ea","article-title":"One thousand consecutive pancreaticoduodenectomies.","volume":"244","author":"Cameron","year":"2006","journal-title":"Ann Surg"},{"issue":"3","key":"coi250008r10","first-page":"126","article-title":"Current surgical management of pancreatic cancer.","volume":"2","author":"Kim","year":"2011","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"coi250008r11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.hpb.2022.02.013","article-title":"Quality of life after pancreatic surgery\u2014a systematic review.","volume":"24","author":"James","year":"2022","journal-title":"HPB (Oxford)"},{"issue":"17","key":"coi250008r12","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"coi250008r13","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. definitive results of the 2000-01 FFCD\/SFRO study.","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"issue":"15","key":"coi250008r14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.4506","article-title":"A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201.","volume":"26","author":"Loehrer","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi250008r15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13014-019-1309-x","article-title":"Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results.","volume":"14","author":"Reyngold","year":"2019","journal-title":"Radiat Oncol"},{"issue":"5","key":"coi250008r16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer.","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"coi250008r17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer.","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"coi250008r18","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy.","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250008r19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S1470-2045(18)30201-8","article-title":"Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.","volume":"19","author":"Noordman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi250008r20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12885-018-4034-1","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.","volume":"18","author":"Noordman","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"coi250008r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7765","article-title":"Individual and population comparisons of surgery and radiotherapy outcomes in prostate cancer using bayesian multistate models.","volume":"2","author":"Beesley","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"coi250008r22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.6004\/jnccn.2023.0030","article-title":"Anal carcinoma, version 2.2023, NCCN Clinical Practice Guidelines in Oncology.","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"coi250008r23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology.","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"coi250008r24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology.","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"coi250008r25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and neck cancers, version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","volume":"18","author":"Pfister","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"coi250008r26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology.","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"coi250008r27","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"2","key":"coi250008r28","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1016\/j.ijrobp.2017.06.361","article-title":"5-Year outcomes of a phase 1 dose escalation study using stereotactic body radiosurgery for patients with clinically localized prostate cancer.","volume":"99","author":"Zelefsky","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"coi250008r29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer.","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"coi250008r30","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer.","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"issue":"6","key":"coi250008r31","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/SLA.0000000000005080","article-title":"Local control and survival after induction chemotherapy and ablative radiation versus resection for pancreatic ductal adenocarcinoma with vascular involvement.","volume":"274","author":"Jolissaint","year":"2021","journal-title":"Ann Surg"},{"issue":"14","key":"coi250008r32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"issue":"10041","key":"coi250008r33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"coi250008r34","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial.","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi250008r35","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi250008r36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1634\/theoncologist.2016-0276","article-title":"Management of cancer in the older age person: an approach to complex medical decisions.","volume":"22","author":"Vallet-Reg\u00ed","year":"2017","journal-title":"Oncologist"},{"issue":"6","key":"coi250008r37","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.21037\/jgo.2019.09.01","article-title":"Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic cancer resection.","volume":"10","author":"Wegner","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"coi250008r38","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00268-015-2948-1","article-title":"Long-term outcomes after total pancreatectomy: special reference to survivors\u2019 living conditions and quality of life.","volume":"39","author":"Watanabe","year":"2015","journal-title":"World J Surg"},{"issue":"6","key":"coi250008r39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.hpb.2017.01.018","article-title":"The outcomes of pancreaticoduodenectomy in patients aged 80 or older: a systematic review and meta-analysis.","volume":"19","author":"Kim","year":"2017","journal-title":"HPB (Oxford)"},{"issue":"2","key":"coi250008r40","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.surg.2014.03.001","article-title":"Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.","volume":"156","author":"Parmar","year":"2014","journal-title":"Surgery"},{"issue":"1","key":"coi250008r41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijrobp.2023.03.036","article-title":"Phase 1 dose escalation study of SBRT using 3 fractions for locally advanced pancreatic cancer.","volume":"117","author":"Reyngold","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi250008r42","doi-asserted-by":"publisher","first-page":"1040673","DOI":"10.3389\/fonc.2023.1040673","article-title":"Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac.","volume":"13","author":"Eijkelenkamp","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"coi250008r43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jgo.2021.07.007","article-title":"Impact of radiotherapy on daily function among older adults living with advanced cancer (RT impact on function in advanced cancer).","volume":"13","author":"Nehlsen","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"25","key":"coi250008r44","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer.","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"coi250008r45","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy.","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2832566\/jamaoncology_reyngold_2025_oi_250008_1749251723.88494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:00:43Z","timestamp":1750417243000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2832566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.0460","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}